Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Deleted in azoospermia protein 4 (DAZ4) is an RNA-binding protein belonging to the DAZ gene family, located on the human Y chromosome[1]. It is expressed primarily in premeiotic germ cells, particularly spermatogonia, and is essential for normal spermatogenesis[1][4][5][7]. DAZ4 likely performs its function by binding to the 3'-untranslated region (3'-UTR) of messenger RNAs (mRNAs), thereby regulating their translation[1][5][7]. Multiple copies of the gene exist within Y-chromosomal palindromic regions, with variation in repeat structure among individuals[1][2]. Mutations or deletions involving DAZ4 are associated with male infertility disorders, notably Y-chromosome microdeletion syndrome and azoospermia[1][2]. DAZ4 is not currently targeted by any drugs and has no established role in therapeutics outside reproductive medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Deleted in azoospermia protein 4 (DAZ4).